Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Variant Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Variant Bio

Variant Bio

Series B

Variant Bio: Harnessing human genetic diversity for innovative therapeutic discovery.

HQ
Seattle, WA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to harness human genetic diversity for innovative therapeutic discovery, Variant Bio focuses on developing life-saving therapies by studying the genes of people with exceptional health-related traits. The company aims to transform drug development, which has become increasingly challenging due to high costs and failure rates, by leveraging unique genetic insights. Their core services include genomic discovery, research partnerships, and a robust pipeline of therapeutic developments.

Notable affiliated individuals and investors include experts in genomics and biotechnology, though specific names are not provided. Variant Bio has made significant strides in the field of therapeutic discovery, contributing to the broader understanding of human genetics and its application in medicine. Their ethical approach and commitment to benefit-sharing underscore their impact on both the scientific community and global health outcomes.

Variant Bio - Similar Companies

Variantyx logo

Variantyx

variantyx.com

Empirico logo

Empirico

empiricotx.com

Variant Pharmaceuticals logo

Variant Pharmaceuticals

variantpharma.com

Sequence Bio logo

Sequence Bio

sequencebio.com

Encoded Therapeutics logo

Encoded Therapeutics

Vibe Bio logo

Vibe Bio

vibebio.com

Actio Biosciences logo

Actio Biosciences

actiobio.com

Galatea Bio logo

Galatea Bio

galatea.bio

Curie.Bio logo

Curie.Bio

curie.bio

Genomenon logo

Genomenon

genomenon.com

Unite Genomics logo

Unite Genomics

Verge Genomics logo

Verge Genomics

vergegenomics.com

Sequegenics logo

Sequegenics

sequegenics.com

Endpoint Health logo

Endpoint Health

Geneicd logo

Geneicd

Variant Bio - Quick Facts

Who are Variant Bio's competitors?

Companies similar to Variant Bio include Variantyx, Empirico, Variant Pharmaceuticals and Sequence Bio.

When was Variant Bio founded?

Variant Bio was founded in 2018.

Where is Variant Bio's headquarters located?

Variant Bio's headquarters is located in Seattle, WA, US.

When was Variant Bio's last funding round?

Variant Bio's most recent funding round was for $105M (USD) in November 2021.

How much has Variant Bio raised to-date?

As of Nov 9, 2021, Variant Bio has raised a total of $129.7M (USD).

How many employees does Variant Bio have?

Variant Bio has 42 employees as of Feb 5, 2024.

Variant Bio - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • Biotech
  • GenAI
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Therapeutics
Tags
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified